摘要:
Technology that is capable of providing objective data for center management while considering reduction of examination time in ophthalmology is provided. A fundus observation apparatus of an embodiment comprises an optical system, image forming part, specifying part, association information generating part and evaluation information generating part. The optical system divides light from a light source into signal light and reference light, generates interference light by superposing the signal light having traveled by way of an eye fundus and the reference light having traveled by way of a reference optical path, and detects the interference light. The image forming part forms a cross sectional image of the eye fundus based on detection results of the interference light. The specifying part analyzes the cross sectional image to specify an abnormal region located in the vicinity of central fovea of the eye fundus. The association information generating part calculates the distance between the central fovea and the abnormal region and generates association information in which the direction of the abnormal region relative to the central fovea and the distance are associated with each other. The evaluation information generating part generates evaluation information for evaluating the state of the eye fundus based on the association information.
摘要:
The present invention provides a pharmaceutical composition for removing drusen, suppressing formation of drusen, and/or treating and/or preventing age-related macular degeneration comprising the compound of formula (I) wherein Ra is independently selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester and cyano, and m is an integer selected from 0 to 4.
摘要:
The purpose of the present invention is to provide a novel system for the delivery of a drug to a posterior segment of the eye. The present invention relates to: a cytophilic peptide-fused high-density lipoprotein (cHDL) which can be used as a carrier for the delivery of a drug to a posterior segment of the eye; a method for producing the cytophilic peptide-fused high-density lipoprotein; a system of the delivery of a drug to a posterior segment of the eye, a pharmaceutical composition, and a system of the delivery of a drug to a posterior segment of the eye, each of which utilizes the cytophilic peptide-fused high-density lipoprotein; and a method for diagnosing, preventing or treating posterior ocular disease.